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Purpose: Major depressive disorder (MDD) has
detrimental effects on health-related quality of life
(HRQoL). We describe the effect of vortioxetine on
HRQoL in MDD patients by using patient-reported
outcome instruments.
Methods: HRQoL was evaluated in 5 short-term
(6–8 weeks), randomized studies of vortioxetine (5–20
mg/d; n ¼ 2155) versus placebo (n ¼ 1316) in adults
with MDD by using the 36-item Short-Form Health
Survey (SF-36), the Quality of Life Enjoyment and
Satisfaction Questionnaire–Short Form, the EuroQol
5-Dimension Questionnaire (EQ-5D), and the 12-item
Health Status Questionnaire in 1 study in elderly
patients. Only patients receiving the approved doses
of vortioxetine 5, 10, 15, or 20 mg/d were included in
the analysis. A random effects meta-analysis was
performed on the 4 adult MDD studies that used the
SF-36. A within-studies mixed model for repeated
measures analysis based on the full analysis set (FAS)
was used unless otherwise speciﬁed. Standardized effect
size (SES) was calculated to reﬂect clinical relevance,
based on a Cohen’s d of 0.2.
Findings: Vortioxetine produced signiﬁcantly better
results compared with placebo in the SF-36 mental
component summary score (5 mg: 2.6, P ¼ 0.001, SES
of 0.22, n ¼ 604; 10 mg: 4.8, Po 0.001, SES of 0.42,
n ¼ 328) and 4 domain scores (vitality, social
functioning, role emotional, and mental health). Vor-
tioxetine was also signiﬁcantly better in the EuroQoL-
5 Dimension Questionnaire Health State score (10 mg:
7.5, P o 0.05, SES of 0.33, n ¼ 86) and Quality of
Life Enjoyment and Satisfaction Questionnaire–Short
Form total score (15 mg: 3.3, P o 0.01, SES of 0.38,
n ¼ 127; 20 mg: 4.5, P o 0.0001, SES of 0.52, n ¼
134) (FAS, last-observation-carried-forward). In the
study of elderly patients, vortioxetine 5 mg (n ¼ 136)
improved 12-item Health Status Questionnaire scoresOctober 2015signiﬁcantly more than placebo (n ¼ 148) for the
domains of health perception (10.4, P o 0.0001, SES
of 0.54), mental health (7.9, P o 0.001, SES of 0.44),
and energy (6.4, P o 0.05, SES of 0.28) (FAS, mixed
model for repeated measures).
Implications: Vortioxetine yielded signiﬁcant,
meaningful HRQoL improvements in 6 MDD studies
of 6 to 8 weeks’ duration. (Clin Ther. 2015;37:2309–
2323) & 2015 The Authors. Published by Elsevier HS
Journals, Inc.
Key words: antidepressant, health-related quality of
life, major depressive disorder, patient-reported out-
comes, vortioxetine.INTRODUCTION
Major depressive disorder (MDD) is a debilitating
medical condition that results in burdens on individ-
uals, families, and society and is a signiﬁcant cause of
disability worldwide. MDD is characterized by the
presence of Z1 major depressive episode (MDE) with
symptoms including depressed mood, loss of interest
or pleasure, disturbed sleep, reduced appetite, low
energy, feelings of guilt and/or low self-worth, and
poor concentration. These problems can lead to
substantial impairments in health-related quality of
life (HRQoL) as well as in the ability to take care of
everyday responsibilities.
Depression recurs in up to 80% of all patients with
MDD who have achieved remission; it can become
chronic (ie, lasting Z2 years) in nearly 20% of2309
Clinical Therapeuticspatients.1,2 The risk of relapse or recurrence, chron-
icity (as measured by the duration of episodes), and
treatment resistance increases with each new MDE.
Thus, treatment to full remission (often deﬁned as a
score r7 on the 17-item Hamilton Depression Scale
or a 50%–80% reduction on this scale compared with
the beginning of treatment) and continued treatment
to prevent relapse or recurrence have high priority in
the management of MDD.3,4 Furthermore, depression
may lead to suicide; the mortality rate due to suicide is
10% to 15% among patients with MDD treated by
psychiatrists.5–7
It is widely recognized that the mood symptoms of
MDD are associated with impairment in perceived
health; reductions in a patient’s physical, psycholog-
ical, and social functioning; and a range of HRQoL
domains related to overall well-being.8–14 Although a
variety of antidepressants are available, only about
one third of acutely treated patients achieve remis-
sion.15 Moreover, even after undergoing multiple
antidepressant therapies, 430% of patients remain
symptomatic in the short term: 2 of 5 patients with
clinical depression do not respond adequately to
antidepressant treatment even after they have
completed fourth-line therapy.16 A recent study of
remitted MDD patients suggests that physical and
mental functioning remained lower in remitted
patients compared with the general population,
highlighting that antidepressant therapies do not
always prevent residual symptoms.17 The results of
the STAR*D (Sequenced Treatment Alternatives to
Relieve Depression) study suggest that greater
depressive symptom severity is directly associated
with poorer HRQoL, with signiﬁcant impairments
seen across psychological, physical, and social
domains.10,18 Therefore, the assessment of HRQoL,
as part of the ongoing evaluation of depression treat-
ment, is necessary for clinicians and patients.14
The assessment of HRQoL depends largely on the
selection of the appropriate HRQoL tools.19 Studies
have demonstrated the relevance of traditional
subjective assessment scales such as the 36-item
Short-Form Health Survey (SF-36), the Quality of Life
Enjoyment and Satisfaction Questionnaire (Q-LES-Q),
the EuroQol 5-Dimension Questionnaire (EQ-5D),
and the Health Status Questionnaire-12 (HSQ-
12)10,18,20,21 for the assessment of HRQoL in patients
with MDD. The rest of the listed scales are generic but
contain different domains capturing various aspects of2310the patient’s functioning and HRQoL, as well as
overall perceptions of quality of life (Table I). The
utilization of the range of different HRQoL measures
enables a comprehensive evaluation of aspects of
HRQoL and functioning relevant to patients with
depression.22
Vortioxetine (Lu AA21004) is an antidepressant
with a multimodal mechanism of action23 approved
in Europe for the treatment of MDEs in adults and
in the United States for the treatment of adults
with MDD. The clinical development program for
vortioxetine that supported the marketing autho-
rization application for MDD or MDE in Europe
entailed 13 short-term studies, 3 long-term extension
studies, and 1 twelve-month relapse-prevention study;
these studies included nearly 6000 patients with a
total exposure of 42000 patient-years. As of January
2015, the total clinical development program for
vortioxetine in these indications entailed 17 short-
term studies, 5 long-term extension studies, and
1 twelve-month relapse-prevention study; this pro-
gram included 49700 patients with a total exposure
of 43450 patient-years.
The aim of the present analysis was to report the effect
of vortioxetine on HRQoL in adult patients with MDD
in randomized placebo-controlled studies, as evaluated by
using various HRQoL instruments.MATERIALS AND METHODS
Vortioxetine Registration Studies
The present across-study comparison of HRQoL
included the 5 short-term (6–8 weeks) studies con-
ducted in adults aged 18 to 75 years (NCT00672958,
NCT00735709, NCT00635219, NCT00839423, and
NCT01140906), and 1 dedicated study in elderly
patients aged Z65 years (NCT00811252) in which
quality of life measures were included for evalua-
tion.24–29 The primary efﬁcacy end point in the short-
term trials was the change from baseline to week 6/8
on the Montgomery-Åsberg Depression Rating Scale
or the 24-item Hamilton Depression Scale total score
to evaluate the effect of vortioxetine on depressive
symptoms. The primary statistical method applied
used either a mixed model for repeated measures
(MMRM) analysis using all available observed
data or an analysis of covariance (ANCOVA) model
using the last-observation-carried-forward (LOCF).
Only patients who received the approved doses ofVolume 37 Number 10
Table I. Evaluation of relative health domains for the assessment of health-related quality of life in patients with major depressive disorder.22
General Domain Concept EQ-5D Q-LES-Q-SF SF-36 HSQ-12
Emotional Irritable — — — —
Lack of pleasure — — — Item 13
Helpless — — — —
Angry — — — —
Crying — — — —
Depressed/sad Item 5 Item 2 Items 5a, 5b, 5c, 9c, 9f, 9h Items 6, 11–15
Overwhelmed — — — —
Hopelessness — — — —
Guilt — — — —
Lack of energy — — Items 9a, 9e, 9g, 9i Item 10
Anxiety Item 5 — Items 5a, 5b, 5c, 9b, 9d Items 6, 9
Motivation Need to push oneself to do things — — Item 5b Item 6
Sleep Sleep — — — —
Appetite Appetite — — — —
Work Work Item 3 Items 3, 12 Items 4a–d, 5a–c, 8 Items 5, 6
Social Family interaction Item 3 Item 6 Items 6, 10 Item 7
Friends — Item 5 Items 6, 10 Item 7
Felt like avoiding others — Item 5 Items 6, 10 Item 7
Wanting to be left alone — Item 5 Items 6, 10 Item 7
Activities of daily living Self-care Item 2 Item 8 Item 3j Items 5, 6
Household activities Items 1, 3 Items 4, 8 Items 3a–f, 8 Items 2, 3, 5, 6
Cognitive function Cognitive function — — — —
Tired/fatigue Tired — — Items 9a, 9e, 9g, 9i Item 10
Body pain Aches Item 4 — Items 7, 8 Item 8
Suicidality Suicidality — — — —
EQ-5D ¼ EuroQol 5-Dimension Questionnaire; Q-LES-Q-SF ¼ Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form; SF-36 ¼ 36-item Short-Form
Health Survey; HSQ-12 ¼ 12-item Health Status Questionnaire.
Adapted with permission from Danchenko et al.22
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Clinical Therapeuticsvortioxetine 5, 10, 15, and 20 mg/d were included in
the analysis.
HRQoL Assessment Measures
The vortioxetine clinical development program also
used various patient-reported outcome measures and
functioning instruments (Table II) to assess overall
HRQoL after consultation with experts in the ﬁeld of
health-related outcomes. The program included the
following validated measures: the SF-36 version
230,31; the Q-LES-Q–Short Form (Q-LES-Q-SF)32,33;
the EQ-5D34; and the HSQ-12 (version 2.0).35
All of the instruments meet established criteria for
the measurement of HRQoL and overall functioning,
and they have been psychometrically validated in
MDD or related disorders. The measures were also
appropriately linguistically adapted and validated to
ensure cross-cultural relevance across the broad range
of countries included within the trials. Finally, the
instruments are clinically well established, widely used
in many disease areas, highly relevant to a depressed
population, and capture information that can provide
substantial value to physicians making treatment
decisions22,36 (Appendices I and II).
36-Item Short-Form Health Survey
The SF-36 version 2 is designed to measure generic
HRQoL concepts relevant across age, disease, and
treatment groups and has been widely used and
validated in patients with MDD37–46 and other mental
health disorders.47–51 The questionnaire consists of 36
questions, which yield a proﬁle of 8 domains: physical
functioning, bodily pain, role physical (limitations in
usual role activities due to physical problems), role
emotional (limitations in usual role activities due to
emotional problems), general health, vitality, social
functioning, and mental health. These domains are
used to derive 2 broader measures: the mental com-
ponent summary (MCS) and the physical component
summary (PCS).30,31 In the PCS, mental dimensions
(including mental health, social functioning, and role
emotional) have negative weights, whereas physical
domains (eg, physical functioning, role physical, bod-
ily pain, general health) are assigned positive weights
of higher values, and energy/vitality and social
functioning are neutrally weighted. Very low PCS
scores indicate severe physical dysfunction, severe
social and role disability, distressful bodily pain,
frequent tiredness, and unfavorable evaluation of2312health status. For the MCS, positive weights are
placed on the mental health, role emotional, social
function, and vitality scales, whereas substantial neg-
ative weights are placed on the physical function and
role physical scales. Very low scores on the MCS
indicate frequent psychological distress and severe
social and role disability due to emotional problems.
In the treatment of a mental illness, no detectable
effect is expected on the physical dimensions of the SF-
36 because patients generally do not report impair-
ment on these dimensions (which tend to be at the
level of the norm in general population at baseline).
This is in contrast to the MCS, in which patients with
mental health disorders have scored signiﬁcantly
lower than the norms of the general population.31,52
Quality of Life Enjoyment and Satisfaction
Questionnaire
The Q-LES-Q32 is a patient-reported outcome
instrument designed to measure enjoyment and sat-
isfaction in various areas of daily life. The short-form
version (Q-LES-Q-SF)53 was designed for and
validated in subjects with a wide range of medical
and psychiatric disorders and has recently been used
extensively in depressed populations.38,54–59 The var-
ious areas of daily functioning assessed by using the
Q-LES-Q-SF32 include those that may be affected by
depression, suggesting its relevance and content
validity. The Q-LES-Q-SF contains 16 items that
assess satisfaction or enjoyment related to physical
health, medications, feelings, work/school, household
duties, leisure-time activities, social relations, and
general activities. The Q-LES-Q was piloted with 95
outpatients experiencing depression to validate the 8
summary scales derived from 93 items reﬂecting the
major domains.
EuroQol 5-Dimension Questionnaire
The EQ-5D is a standard generic measure of
HRQoL, used mainly to assess the value of health
interventions in cost-utility studies.60 It is often used
to complement other quality of life measures and has
been applied in numerous studies of depression.38,61,62
The EQ-5D consists of 2 sections (the EQ-5D descrip-
tive system and the EQ visual analog scale [VAS]) and
has been validated in populations with depres-
sion.63,64 The EQ-5D descriptive system includes the
5 domains of mobility, self-care, usual activities, pain/
discomfort, and depression/anxiety, which are ratedVolume 37 Number 10
Table II. Overview of patient-reported outcome measures used to assess health-related quality of life (HRQoL) in the vortioxetine clinical
development program
Study Study Design
Placebo
(n ¼ 1012)
Vortioxetine
(n ¼ 1833)
SF-36 Domain
Scores and
Component
Summaries
Q-LES-Q-
SF Total
and Single-
Item Scores
EQ-5D
Utility
Index
HSQ-12
Domain
Scores
NCT0067295824 6-week, ﬁxed-dose vortioxetine
(5 mg)
286 5 mg: 292 X
NCT0073570925 8-week, ﬁxed-dose vortioxetine
(1, 5, or 10 mg)
139 1 mg: 139 X
5 mg: 139
10 mg: 139
NCT0063521926 8-week, ﬁxed-dose vortioxetine
(2.5, 5, or 10 mg), active
reference (duloxetine 60 mg)
145 2.5 mg: 155 X
5 mg: 155
10 mg: 151
NCT0083942327 6-week, ﬁxed-dose vortioxetine
(5 or 10 mg), active reference
(venlafaxine 225 mg)
139 5 mg: 108 X X
10 mg: 100
NCT0114090628 8-week, ﬁxed-dose vortioxetine
(15 or 20 mg), active
reference (duloxetine 60 mg)
158 15 mg: 149 X
20 mg: 151
NCT0081125229 8-week, ﬁxed-dose vortioxetine
(5 mg), active reference
(duloxetine 60 mg), in elderly
subjects
145 5 mg: 155 X
SF-36 ¼ 36-item Short-Form Health Survey; Q-LES-Q-SF ¼ Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form; EQ-5D ¼ EuroQol 5-Dimension
Questionnaire; HSQ-12 ¼ 12-item Health Status Questionnaire. I.
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Clinical Therapeuticsby patients using a 3-point Likert scale (1 = no
problems; 2 = some problems; 3 = extreme problems).
The EQ-5D VAS measures the patient’s perception of
his or her health state on a vertical graduated VAS
that ranges from 0 to 100 (worst to best imaginable
health state). The results of the EQ-5D VAS are the
focus of the analyses presented in this article.34
12-Item Health Status Questionnaire
The HSQ-12 is a generic, patient-reported outcome
instrument designed to evaluate physical, emotional,
and social functioning, with a focus on the elderly.
The HSQ-12 was developed from the original 39-item
HSQ, from which the SF-36 was also derived; it thus
demonstrates content validity similar to the SF-36. As
with the SF-36, items in the HSQ-12 cover important
aspects of health that are known to be adversely
affected by mood disorders (including MDD)65 and
advanced age.66 The HSQ-12 displays high predictive
validity for patients with depression.
The HSQ-12 includes 12 items that use Likert-type
single-stimulus responses, consisting of between 3 and
6 possible options. To score the HSQ-12, responses
are transformed to a scale of 0 to 100, and 8 scales are
calculated from the 12 items (thus maintaining the
8-domain structure of the SF-36). Six of the 8 scales
contain single items, with 2 scales (physical function-
ing and mental health) each containing 3 items
averaged together. A higher score indicates better
health.35
Statistical Methods
A random effects meta-analysis67 was performed
on the results from the short-term vortioxetine studies
by using both MMRM and ANCOVA, LOCF (as a
sensitivity analysis) for individual studies based on the
full analysis set (FAS) at the end of study period. For
the HRQoL variables used only in individual studies,
an MMRM analysis was conducted, with the excep-
tion of the Q-LES-Q-SF, for which ANCOVA, LOCF
was conducted because this instrument was only
administered once after baseline and at the last visit
(upon completion or withdrawal). MMRM was
chosen as the primary analysis based on the advan-
tages related to estimation bias,68 with MMRM
models run on observed cases with freely varying
mean and covariance structures; treatment and center
were used as ﬁxed factors and baseline score as a
covariate interacting with visit. The ANCOVA, LOCF2314analysis was used as a sensitivity analysis with no
direct or indirect comparison of the 2 analysis
methods. The standardized mean differences to
placebo interpreted as Cohen’s d standardized effect
size (SES) were used (using the standard 0.2 threshold
for clinical relevance, based on the research of Leucht
et al69). This method allows a comparison of the
magnitude of the effect sizes between studies and the
different assessment tools. All analyses were
performed by using SAS version 9.1 (SAS Institute,
Inc, Cary, North Carolina).
RESULTS
Patient Population
The populations in the 6 short-term MDD studies
in adults were similar with regard to disease character-
istics and demographic characteristics, with a few
exceptions. The mean age of the patients ranged
between 42 and 47 years in the individual studies
(overall individual study range, 18–75 years), and
66% of participants were women (overall individual
study proportion of women, 60.3%–76.0%). Mean
age in the dedicated elderly study was 71 years, and
66% of patients were women. In the 5 short-term
studies in nonelderly adults, most patients were white
(81%), 13% were black, and 6% were Asian. There
were some differences in racial composition across the
studies because they were conducted in different geo-
graphical regions.
36-Item Short-Form Health Survey
Assessment of SF-36 in the vortioxetine clinical
trial program was calculated by using the 2 broader
components of health: the MCS and the PCS.30,31 The
impact of vortioxetine on more speciﬁc HRQoL
domains from the SF-36 was also assessed to present
a more complete picture of MDD-related outcomes.
SF-36 MCS Score
The SF-36 MCS was calculated for 4 short-term
studies conducted in adults and reported as change
from baseline versus placebo at study end point (week
6/8). The 5-mg dose of vortioxetine was included in all
4 studies and separated from placebo (P o 0.05) in
2 of them, with the mean difference from placebo
ranging between 3.4 and 4.8 points. Vortioxetine
10 mg was also included in the 3 studies and
separated from placebo (P o 0.05) in each, with a
mean difference from placebo of 4.0 and 6.2 points.Volume 37 Number 10
I. Florea et al.In the meta-analysis of the mean change from baseline
in SF-36 MCS score (FAS, MMRM) at week 6/8, the
overall mean difference of vortioxetine from placebo
was statistically signiﬁcant: 2.6 points (P = 0.001) in
favor of vortioxetine 5 mg, and 4.8 points (P o
0.001) in favor of vortioxetine 10 mg (Figure 1). The
clinical relevance of the results was supported by the
SES, which exceeded the standard 0.2 threshold
(vortioxetine 5 mg, SES of 0.22 [range in the
individual studies (Table II), 0.06–0.38]; vortioxetine
10 mg, SES of 0.42 [range in the individual studies,
0.35–0.49]; FAS, MMRM) (Table III).
The ANCOVA, LOCF analyses of the individual
studies produced results similar to those in the
MMRM analyses, with the exception that the 5- and
10-mg doses did not separate from placebo in studyNCT00839423
Vortioxetine 5 mg
Vortioxetine 10 mg
Vortioxetine 5 mg
Vortioxetine 10 mg
Vortioxetine 5 mg
Vortioxetine 5 mg
Vortioxetine 10 mg
Vortioxetine 5 mg
Vortioxetine 10 mg
NCT00635219
NCT00735709
NCT00672958
Meta-analysis
Worse Than Placebo Better Than Placebo
Difference From placebo
−4 0 4 8
Figure 1. Meta-analysis of change from baseline on the 3
summary (full analysis set, mixed model for re
October 2015NCT00839423. The ANCOVA, LOCF meta-analysis
yielded results similar to the MMRM meta-analysis.SF-36 PCS Score
The MMRM meta-analysis of the mean change
from baseline in the SF-36 PCS score at week 6/8
exhibited numerically greater changes for vortioxetine
but not a statistically signiﬁcant separation from
placebo in the individual studies nor in the meta-
analysis of the 4 short-term studies (vortioxetine 5 mg,
change of 0.49, P ¼ 0.192, SES of 0.08, n ¼ 0.06;
vortioxetine 10 mg, change of 0.52, P ¼ 0.282, SES of
0.08, n ¼ 0.08; FAS, MMRM). The meta-analysis of
SF-36 PCS results were analyzed by using ANCOVA,
LOCF and yielded similar results.12 16 20
2.62 (1.02 to 4.22)
4.84  (3.10 to 6.57)
604:591
328:344
0.84 (−1.51 to 3.20) 250:247
4.94 (2.26 to 7.63)
3.44 (0.78 to 6.10)
124:129
130:129
3.95 (1.11 to 6.79) 120:125
2.60 (−0.21 to 5.42) 126:125
6.21 (2.41 to 10.01) 84:90
4.82 (1.16 to 8.48) 98:90
Difference (95% CI) n (Vortioxetine:placebo)
6-item Short-Form Health Survey mental component
peated measures).
2315
Table III. Mean change from baseline in the 36-item Short-Form Health Survey (SF-36) mental component summary at week 6/8 (full analysis set,
mixed model for repeated measures) in all short-term studies using the SF-36.
Study Treatment
Duration,
wk No. Mean
Mean Difference
From Placebo SE
Lower
95% CI
Upper
95% CI SES P Heterogeneity P
NCT00839423 Placebo 6 90 12.58 — — — — — — —
Vortioxetine 5 mg 6 98 17.40 4.82 1.86 1.16 8.48 0.38 0.010 —
Vortioxetine 10 mg 6 84 18.78 6.21 1.93 2.41 10.01 0.49 0.001 —
NCT00635219 Placebo 8 125 11.91 — — — — — — —
Vortioxetine 5 mg 8 126 14.51 2.60 1.43 –0.21 5.42 0.23 0.069 —
Vortioxetine 10 mg 8 120 15.85 3.95 1.45 1.11 6.79 0.35 0.007 —
NCT00735709 Placebo 8 129 9.43 — — — — — — —
Vortioxetine 5 mg 8 130 12.87 3.44 1.35 0.78 6.10 0.32 0.011 —
Vortioxetine 10 mg 8 124 14.37 4.94 1.37 2.26 7.63 0.46 o0.001 —
NCT00672958 Placebo 6 247 11.80 — — — — — — —
Vortioxetine 5 mg 6 250 12.65 0.84 1.2 –1.51 3.20 0.06 0.481 —
Meta-analysis Placebo 6/8 591 — — — — — — — —
Vortioxetine 5 mg 6/8 604 — 2.62 0.82 1.02 4.22 0.22 0.001 0.268
Vortioxetine 10 mg 6/8 328 — 4.84 0.88 3.10 6.57 0.42 0.001 0.642
SES – standardized effect size.
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I. Florea et al.SF-36 Domain Scores
The meta-analysis of the mean changes from base-
line in SF-36 domain scores at week 6/8 (FAS,
MMRM) demonstrated a signiﬁcant improvement
for vortioxetine 5 mg (P o 0.05) versus placebo in
increasing the role physical, vitality, social function-
ing, role emotional, and mental health scores
(Figure 2). In addition, vortioxetine 10 mg was
statistically signiﬁcantly (P o 0.05) more effective
than placebo in increasing each of the domain scores,
except for physical functioning. The calculated
Cohen’s d using a 0.2 threshold indicated clinical
relevance of the SES and supports the results of the
meta-analysis, with all separations from placebo
favoring vortioxetine at week 6/8.
Q-LES-Q-SF Scores
In the analysis of the mean change from baseline in
Q-LES-Q-SF scores at week 8 (ANCOVA, LOCF),
vortioxetine 15 mg and 20 mg demonstrated a
statistical separation from placebo (P r 0.05) for
both the total score (vortioxetine 15 mg vs placebo,
change of 3.3, SES of 0.38, n ¼ 127; vortioxetine
20 mg vs placebo, change of 4.5, SES of 0.52, n ¼ 1346
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M
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Physical Fu
Figure 2. Change from baseline on the 36-item Short-F
mixed model for repeated measures). *P o 0
October 2015[ANCOVA, LOCF]) and single-item 16 overall life
satisfaction and contentment score (vortioxetine 15
mg vs placebo, change of 0.35, SES of 0.36, n ¼ 139;
vortioxetine 20 mg vs placebo, change of 0.44, SES of
0.45, n ¼ 142 [ANCOVA, LOCF]). The calculated
Cohen’s d using a 0.2 threshold indicates the clinical
relevance of the SES.
EQ-5D Health State Score
In the analysis of the mean change from baseline in
EQ-5D health state score at week 6 (FAS, MMRM),
vortioxetine 10 mg demonstrated a statistically sig-
niﬁcant separation from placebo (P ¼ 0.027), with a
mean difference from placebo of 7.5 and an SES of
0.33 (n ¼ 86). Vortioxetine 5 mg did not separate
from placebo (P ¼ NS), with a mean difference from
placebo of 2.5 and an SES of 0.11 (n ¼ 104).
The calculated Cohen’s d indicates the clinical rele-
vance of the SES and supports the results of the
MMRM analysis, with all separations from placebo
in favor of vortioxetine. Analysis of overall health
state demonstrated signiﬁcant beneﬁts in favor of
vortioxetine 5 mg (change of 0.07; P o 0.05; SES of
0.29; n ¼ 106) and 10 mg (change of 0.09; Po 0.05;Vortioxetine 5 mg Vortioxetine 10 mg
‡
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nctioning
Role Em
otional
Role Physical
Social Functioning
Vitality
orm Health Survey domain scores (full analysis set,
.05, †P o 0.01, ‡P o 0.001.
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Clinical TherapeuticsSES of 0.36; n ¼ 90) compared with placebo after 6
weeks of treatment. Analysis of the results using
ANCOVA, LOCF methods yielded similar results.
HSQ-12 Scores
The HSQ-12 was included in the dedicated elderly
study (NCT00811252) to assist in understanding the
functional beneﬁts of vortioxetine in elderly patients with
MDD. In the MMRM analyses of the mean change from
baseline in HSQ-12 domain scores at week 8, vortiox-
etine 5 mg demonstrated a statistically signiﬁcant separa-
tion from placebo on the domains of health perception
(change of 10.35; P o 0.0001; SES of 0.54; n ¼ 137),
mental health (change of 7.94; P o 0.001; SES of 0.44;
n ¼ 137), and energy (change of 6.39; Po 0.05; SES of
0.28; n ¼ 137). The SES supported the results of the
MMRM analysis, with all separations from placebo in
favor of vortioxetine. Analysis of the results using
ANCOVA, LOCF methods yielded similar results.
DISCUSSION
Depressive disorders were identiﬁed as a leading cause
of disease burden in the 1990 and 2000 Global
Burden of Disease studies,70,71 with depressive disor-
ders ranked as the fourth leading cause of burden in
2000 (equivalent to 4.4% of all disability-adjusted
life-years), after perinatal conditions, lower respira-
tory tract infections, and HIV/AIDS.71 MDD was also
identiﬁed as the leading cause of disability, responsible
for 13.4% of the years of life lived with a disability in
women and 8.3% in men. The Medical Outcomes
Survey found that compared with a normalized pop-
ulation, patients with MDD demonstrate signiﬁcant
impairments in HRQoL, including reductions in daily
life; physical, psychological, and social functioning;
and overall well-being.9,10,14,17
To comprehensively evaluate HRQoL beneﬁts in
patients with MDD, the assessment of at least 3 speciﬁc
domains of health (physical, psychological, and social)
has been recommended, using various subjective and
objective assessments such as symptoms, ability to
function, and overall disability.32 HRQoL instruments
were incorporated into the vortioxetine clinical devel-
opment program to evaluate the treatment effect on
patients’ physical, emotional, and social health, and on
general daily life.31,32,37,65,72,73 The SF-36, Q-LES-Q,
and EQ-5D instruments are validated measures of
HRQoL and have been used in patients with MDD,
as well as other mood disorders.30,31,65,73-902318The HSQ-12 shares its origins with the SF-36 and
was adapted by the developers to be appropriate for an
elderly population.66 The instruments are multi-
dimensional and have achieved satisfactory evidence of
validity and reliability for mood disorders and other
psychiatric conditions20,31,63,64,73,91–94 and, in the case
of the HSQ-12, in elderly populations.66 Although the
safety and efﬁcacy of available antidepressant treatments
have been extensively evaluated by using various clinical
assessment measures, few data are available regarding
their effects on HRQoL.
Overall quality of life for ﬂuoxetine 90 mg extended
release (ER) was assessed in a multicenter, open-label
study of adult patients with MDD by using the SF-36.
Statistical improvement was seen for general mental
health, role limitations resulting from emotional prob-
lems, and vitality regardless of prior therapy.81 In an
open-label investigation of escitalopram in patients with
MDD, improvements in the SF-36 ranged from an
increase of 12.7 points in physical functioning to an
increase of 63.0 points on role emotional limitations.44
Improvements on all 8 dimensions, as well as on the
mental health and physical health subscales, were
statistically signiﬁcant. The effect of duloxetine on
quality of life was assessed in an 8-week study of elderly
MDD patients, in which it achieved improvements from
baseline on the SF-36 PCS scores (least-squares mean
change, 0.61 vs –1.14; P ¼ 0.047) but not SF-36 MCS
scores (8.33 vs 6.18) relative to placebo.41,95 In a
nonrandomized controlled trial of 62 outpatients with
unipolar and bipolar depression, patients treated with
duloxetine were more likely to demonstrate an increase
in the quality of life scores (SF-36 percentage of
improvement [mean (SD)], 6.35 [9.66] vs –2.58 [9.98];
P o 0.001) than were control subjects.96
A recent, secondary, post hoc analysis of a double-
blind, placebo-controlled trial of desvenlafaxine in pa-
tients with MDD evaluated the relationship of depressive
symptoms and functional outcomes.97 Desvenlafaxine-
treated patients in the modiﬁed intention-to-treat sample
exhibited signiﬁcantly greater improvement in several
functional outcomes in the responder, nonanxious,
and normal-energy patient subgroups. Functional
improvement after 12 weeks of desvenlafaxine treat-
ment was greater in these patient subgroups and
was predicted by an early improvement in de-
pressive symptoms in employed MDD patients.
In a randomized study of venlafaxine ER in adult
outpatients with recurrent MDD, better overallVolume 37 Number 10
I. Florea et al.psychosocial functioning was observed among pa-
tients randomly assigned to receive venlafaxine ER
(n ¼ 129) versus placebo (n ¼ 129), with signiﬁcant
differences at end point on SF-36 role function–emo-
tional, the Q-LES-Q, and the Social Adjustment Scale–
Self-Report total, and work, house work, social/
leisure, and extended-family factor scores (P r
0.05). After 2 years of treatment, signiﬁcant differ-
ences favored venlafaxine ER (n ¼ 43) versus placebo
(n ¼ 40) on SF-36 vitality and role function–emo-
tional, the Q-LES-Q Life Enjoyment Scale–Short
Version, and Social Adjustment Scale–Self-Report
total, social/leisure, and extended-family factor scores
(P r 0.05).42 Although these studies suggest the
clinical beneﬁts of available antidepressant therapies
on HRQoL, there is limited assessment of any
available antidepressant therapy beyond the SF-36.
The present analysis of HRQoL was performed on
the short-term, placebo-controlled pivotal registration
studies of vortioxetine in adults with MDD. The results
of the individual clinical studies are supportive of
vortioxetine’s efﬁcacy proﬁle in depressive symptoms
and demonstrated a statistically signiﬁcant difference
from placebo in favor of vortioxetine treatment for
patients with MDD. In terms of speciﬁc quality of life
improvements, vortioxetine separated from placebo (Po
0.05) at week 6/8 on SF-36 MCS score (evaluated at 5
and 10 mg/d). The effect on SF-36 MCS was clinically
relevant, as supported by the SES, which exceeded the
Cohen’s d threshold of 0.2. In depression, reaching a
meaningful separation from placebo is rare, and
although the results suggest the minimal important
difference, when looking at the changes over time,
signiﬁcant and meaningful improvements within a group
can also be noted. The meta-analysis of all the short-term
studies in adults support the results of the individual
studies and showed a statistically signiﬁcant difference
from placebo in favor of vortioxetine and an increased
effect with increasing dose. The favorable effect of
vortioxetine (at 5 and 10 mg/d) was corroborated by
the associated statistically signiﬁcant increases in all 4 of
the SF-36 domain scores (vitality, social functioning, role
emotional, and mental health) that are most relevant to
mental health conditions. The SF-36 PCS score is a
component score based on physical well-being. The
patients included in the short-term vortioxetine studies
in adults with MDD were generally in good physical
health (as prespeciﬁed on the clinical trial inclusion
criteria), and therefore no or limited improvement inOctober 2015the score was expected or reported. The improvement in
HRQoL observed with the SF-36 MCS score is sup-
ported by the separation from placebo (P o 0.05) at
week 6/8 in favor of vortioxetine in the EQ-5D score and
Q-LES-Q total and life-satisfaction scores. The effect on
the Q-LES-Q and EQ-5D in NCT01140906 and
NCT00839423, respectively, were supported by the
SES for vortioxetine 10, 15, and 20 mg/d.
These improvements in HRQoL were replicated in
the dedicated elderly study, in which vortioxetine
5 mg/d separated from placebo (P o 0.05) on the
HSQ-12 subscale scores for health perception, mental
health, and energy at week 8. The overall improve-
ments in HRQoL in the elderly populations were
similar to those seen in the overall adult MDD
population and are of particular importance given
the prevalence and burden of depressive symptoms in
this speciﬁc patient group.
This evaluation of HRQoL in the vortioxetine
clinical trial program does have certain limitations.
Not all instruments were used in all clinical trials, with
3 of the 4 assessment tools only used in 1 study each.
Furthermore, the trial designs include doses ranging
from 1 to 20 mg, with only 1 trial that assessed
quality of life using the 15- and 20-mg doses. In
addition, the SF-36 was not evaluated in the higher
dose study, and the overall negative clinical efﬁcacy
results of the NCT00672958 trial also directly reﬂect
a lack of effect on the SF-36 MCS in that trial; this
potentially confounds the perceived treatment beneﬁt
of vortioxetine on the SF-36 MCS. The patient popu-
lations in the clinical trials were prespeciﬁed to be of
good overall general health, limiting any potential re-
sults on physical symptoms of the SF-36 PCS, as well
as any potential subgroup ﬁndings of the Q-LES-Q
and HSQ-12, which contain physical components.
These limitations affect the potential generalizability
of these ﬁndings beyond the clinical trial setting and
suggest the need for future studies to evaluate the
effect of vortioxetine on overall physical functioning.
CONCLUSIONS
MDD is a disabling and chronic disease that dimin-
ishes well-being, functioning, and quality of life.
HRQoL is recognized as an important outcome
measure in the management of patients with MDD,
with several multidimensional assessment scales (in-
cluding the SF-36, EQ-5D, HSQ-12, and Q-LES-Q-SF)
validated for use in a population with depression.2319
Clinical TherapeuticsTreatment with vortioxetine, which is effective in the
short-term treatment of patients with MDD, was
associated with signiﬁcant, clinically meaningful im-
provements in HRQoL, including speciﬁc improve-
ments on the SF-36 mental health domains of vitality,
social functioning, role emotional, and mental health,
which may translate into meaningful clinical beneﬁts.
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Table AI. Overview of patient-reported outcome health-related quality of life (HRQoL) and functioning instruments.
Variable SF-36 Version 2 Q-LES-Q-SF EQ-5D HSQ-12
Number of items 36 items assessing patient-
reported descriptions of
their HRQoL, yielding 8
domains including:
physical functioning; role
limitations due to physical
problems; bodily pain;
general health perception;
social functioning; mental
health; energy and vitality;
role limitations due to
emotional problems;
health transition
16 items designed to assess
individuals’ quality of life
and satisfaction,
including: physical health;
physical function; mood
and well-being; living
situation; economic
situation; household
duties; sex life; leisure
time activities; family
and social relations;
satisfaction with
medication; overall
life satisfaction and
contentment as separate
items
EQ-5D Index: 5 items
assessing patient-reported
descriptions of their own
health state, including:
mobility, self-care, usual
activities, pain/
discomfort, and
depression/anxiety
12 items assessing patient-
reported descriptions of
their HRQoL, including
the same 8 domains as the
SF-36
Includes a VAS for rating
own health status
Response format 5-point Likert scale (for most
items)
5-point Likert scale For EQ-5D index: 3-point
Likert scale
Likert-scale responses with
3–6 options depending on
the itemFor EQ-5D VAS rating of
own health state status:
3-point scale for physical
functioning
 Vertical VAS: 0 (“worst
imaginable health state”)
to 100 (“best imaginable
health”)
Recall period SF-36 version 2 (standard):
In the past 4 weeks (used
in long-term study
11985A)
During the last week Today During the past 4 weeks
SF-36 version 2 (acute): In
the past week (used in
short-term studies 303,
305, 11492A, 11984A)
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Table AI. (continued).
Variable SF-36 Version 2 Q-LES-Q-SF EQ-5D HSQ-12
Scoring summary Scores for the 8 domains are
transformed into a 0–100
score (higher scores
indicate better HRQoL)
As well as the 8 individual
domain scores, 2
summary scores are
calculated: a mental
component summary and
a physical component
summary
Scores for 14 domains are
summed to produce a
total score. The score can
be converted and
expressed as a percentage
maximum score (using a
linear translation) ranging
from 0%–100% to
facilitate comparison
across disease groups.1
Higher scores indicate
better HRQoL
For the EQ-5D index, a
health state is deﬁned by a
5-digit number resulting
from the response for each
item. This can be
transformed into a utility
index score calibrated
between 0 and 1, with
higher scores meaning
better health-related
quality of life
Scores for the 8 domains are
transformed into a 0–100
score (higher scores
indicate better HRQoL)
For the VAS, the score is the
value chosen on the 0–100
scale. Higher scores
equates to higher HRQoL
Satisfaction with medication
and overall life satisfaction
and contentment are
scored separately1
SF-36 ¼ 36-item Short-Form Health Survey; Q-LES-Q-SF ¼ Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form; EQ-5D ¼ EuroQol 5-Dimension
Questionnaire; HSQ-12 ¼ 12-item Health Status Questionnaire; VAS ¼ visual analog scale.
1 Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993;29:321–326.
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Table AII. Summary of instrument psychometric properties.
Property Criteria for Acceptability1
SF-36v2 (for Both Acute
And Chronic Versions) Q-LES-Q-SF EQ-5D HSQ-12
Construct validity:
principal
components
factor analysis
All items loading on the
ﬁrst un-rotated factor
40.40 to support
unidimensionality
No item redundancy (all
inter-item correlations
should be o0.80)
For a general
population,* the
acceptable factor
loading for the MCS
and PCS summary
scales strongly support
the 2-dimensional
model of HRQoL2
For GAD patients, the
moderate but
signiﬁcant correlations
suggest that the
Q-LES-Q-SF is related
to, but not redundant
with, other measures
of illness severity, and
assesses an important
symptom dimension
that is not evaluated
by established clinical
severity of illness
measures3
Not described Acceptable construct
validity suggesting
physical and mental
health scales could be
obtained by summing
the scales for each
factor for people on
low incomes, as with
the PCS and MCS of
the SF-36 or SF-124
For a general
population,* no items
are redundant2
Data for patients with
depression are not
available
Speciﬁc data for patients
with depression are
not available
Factor analysis of the full
93-item version for
patients with severe
mental illness, from
which the Q-LES-Q-SF
is derived, indicates
that the Q-LES-Q
seems to measure the
construct it purports
to measure5,6
For patients with
schizophrenia, an
acceptable inter-item
correlation for the
Q-LES-Q SF conﬁrms
that no items are
redundant (o0.80)
Speciﬁc data for patients
with depression are
not available
Construct validity:
item convergent
validity
Item-scale correlation
Z0.40
For a general population*
SF-36 version 2 item-
scale correlations
For a psychiatric
population,† all items
correlated signiﬁcantly
Not described For older people,
including people with
depression, intra-scale
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Table AII. (continued).
Property Criteria for Acceptability1
SF-36v2 (for Both Acute
And Chronic Versions) Q-LES-Q-SF EQ-5D HSQ-12
indicate the individual
domain scales, PCS,
and PCS met criteria
for convergent validity2
to the total score,
conﬁrming item
convergent validity8
(Z0.4) correlation7
conﬁrms item
convergent validity
Speciﬁc data for patients
with depression are
not available
28% of the validation
population included
those with mood
disorders,8 thereby
supporting the validity
of this scale in
depressed populations
Data for patients with
depression are not
available
Internal
consistency
reliability
Cronbach’s α coefﬁcient
40.70
For clinically depressed
patients the MCS,
PCS, and all 8 health
domains met criterion
for internal consistency
reliability2
For a psychiatric
population† that
includes those with
mood disorders, the
Q-LES-Q-SF met
criterion for internal
consistency
reliability5,8
Internal consistency
reliability criterion for
EQ-5D index score met
for other conditions9
No data are available for
patients with
depression
For people on low
income, internal
consistency reliability
criterion for HSQ-12
met (Cronbach’s α
Z0.70)4
Speciﬁc data for patients
with depression are
not availableSpeciﬁc data for patients
with depression are
not available
Test–retest
reliability
ICC Z0.70 Generally, the SF-36v2
shows high reliability
for a general
population2,*
Threshold ICC Z0.70
suggest test–retest
reliability met by the
Q-LES-Q-SF for a
psychiatric population,
that includes those
with mood disorders8,†
Test–retest reliability
met by the EQ-5D
Index and EQ-5D
VAS for other
conditions9
For cardiology patients,
threshold ICC Z0.70
for test–retest
reliability generally met
by the HSQ-127Data for test–retest
reliability in patients
with depression are
not available
No data are available for
depression population
Speciﬁc data for patients
with depression are
not availableSpeciﬁc data for patients
with depression are
not available
Concurrent Validity Criteria for acceptability
depend on the degree
of conceptual
similarity between the
SF-36v2 shows moderate
to high correlation
with concurrent
For a GAD population
and patients with a
psychiatric diagnosis†
that includes those
For patients with
depression and anxiety
disorders, the EQ-5D
shows moderate to
Although no direct
evidence of concurrent
validity exists for the
HSQ-12, the
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Table AII. (continued).
Property Criteria for Acceptability1
SF-36v2 (for Both Acute
And Chronic Versions) Q-LES-Q-SF EQ-5D HSQ-12
questionnaire and
other measures:
Small correlation ¼
0.20 o r o 0.40
Moderate correlations:
r 4 0.40
measures2 indicating
concurrent validity
with mood disorders,
the Q-LES-Q-SF shows
moderate to high
correlation with
concurrent measures3,8
high correlation with
concurrent measures,
indicating concurrent
validity11,12
concurrent validity
could be inferred from
the SF-36 and SF-12
concurrent validity
data, as the HSQ-12
was derived from the
HSQ-39 (the parent
questionnaire of the
SF-36 and SF-12)
Speciﬁc data for patients
with depression are
not available
In particular, the MCS
shows acceptable
correlation with the
SDS and depression-
related items in 3 other
questionnaires1
Known groups
validity/clinical
validity
Instrument scores are
expected to differ at a
statistically signiﬁcant
level between known
groups or between
different clinical
parameters
In both acute and
standard versions of
the SF-36v2, the health
domain scales and
component summary
measure that primarily
assess mental health
(MH, RE, SF, VT, and
MCS) have been
shown to discriminate
between patients with
and without a mental
health condition,
including depression.
In particular, the MH
domain and MCS have
been shown to be
useful in screening for
psychiatric disorders2
Also, all 8 SF-36v2
domain scores have
been shown to
distinguish between a
For patients with a
psychiatric diagnosis†
that includes those
with mood disorders,
Q-LES-Q-SF score
correlated signiﬁcantly
with the clinician
global impression of
severity and patient
global impression of
severity (r ¼ 0.89 and
r ¼ 0.43, respectively)8
The EQ-5D index score
was able to distinguish
between depressed and
nondepressed
patients13
For people on low
incomes, the HSQ-12
discriminated between
people with and
without a disability4
Moreover, all 8 scales
of the HSQ-12 could
distinguish between
older patients with and
without self-reported
health problems,
including people with
and without
depression7
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Table AII. (continued).
Property Criteria for Acceptability1
SF-36v2 (for Both Acute
And Chronic Versions) Q-LES-Q-SF EQ-5D HSQ-12
nonclinical sample,
depressed patients,
and schizophrenic
patients14
SF-36v2 ¼ 36-item Short-Form Health Survey (version 2); Q-LES-Q-SF ¼ Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form; EQ-5D ¼ EuroQol
5-Dimension Questionnaire; HSQ-12 ¼ 12-item Health Status Questionnaire; MCS ¼ mental component summary; PCS ¼ physical component summary;
GAD ¼ generalized anxiety disorder; ICC ¼ intra-class coefﬁcient; VAS ¼ visual analogue scale.
1Arbuckle R, Frye MA, Brecher M, et al: The psychometric validation of the Sheehan Disability Scale (SDS) in patients with bipolar disorder. Psychiatry Res 2009,
165:163–174.
2Maruish ME. User’s manual for the SF-36v2 Health Survey (3rd ed.). Lincoln, RI: QualityMetric Inc; 2011.
3Wyrwich K, Harnam N, Revicki DA, Locklear JC, Svedsäter H, Endicott J: Assessing health-related quality of life in generalized anxiety disorder using the Quality Of
Life Enjoyment and Satisfaction Questionnaire. International Clinical Psychopharmacology 2009, 24:289–295.
4Barry TL, Kaiser KL, Atwood JR: Reliability, validity, and scoring of the Health Status Questionnaire-12 version 2.0. J Nurs Meas 2007,15:24–35.
5Pitkanen A, Valimaki M, Endicott J, et al: Assessing quality of life in patients with schizophrenia in an acute psychiatric setting: Reliability, validity and feasibility of
the EQ-5D and the Q-LES-Q. Nord J Psychiatry 2012, 66:19–25.
6Bishop SL, Walling DP, Dott SG, Folkes CC, Bucy J: Reﬁning quality of life: validating a multidimensional factor measure in the severe mentally ill. Qual Life Res 1999,
8:151–160.
7Pettit T, Livingston G, Manela M, Kitchen G, Katona C, Bowling A: Validation and normative data of health status measures in older people: the Islington study. Int
J Geriat Psychiatry 2001, 16:1061–1070.
8Stevanovic DA: Quality of Life Enjoyment and Satisfaction Questionnaire short form for quality of life assessments in clinical practice: a psychometric study.
J Psychiatr Ment Health Nurs 2011,18:744–750.
9King JT, Jr., Tsevat J, Roberts MS: Measuring preference-based quality of life using the EuroQol EQ-5D in patients with cerebral aneurysms. Neurosurgery 2009,
65:565–572.
10Konig HH, Ulshofer A, Gregor M, et al: Validation of the EuroQol questionnaire in patients with inﬂammatory bowel disease. Eur J Gastroenterol Hepatol 2002,
14:1205–1215.
11Konig HH, Born A, Gunther O et al: Validity and responsiveness of the EQ-5D in assessing and valuing health status in patients with anxiety disorders. Health Qual
Life Outcomes 2010, 8:47.
12Gunther OH, Roick C, Angermeyer MC, Konig HH: The responsiveness of EQ-5D utility scores in patients with depression: a comparison with instruments
measuring quality of life, psychopathology and social functioning. J Affect Disord 2008, 105:81–91.
13Schrag A, Selai C, Jahanshahi M, Quinn NP: The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with
Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000, 69:67–73.
14Pukrop R, Schlaak V, Moller-Leimkuhler AM, et al: Reliability and validity of quality of life assessed by the Short-Form 36 and the Modular System for Quality of Life
in patients with schizophrenia and patients with depression. Psychiatry Research 2003, 119:63–79.
*General US population.
†Psychiatric diagnosis included schizophrenia, schizotypal, and delusional disorders; mood disorders (including depression); anxiety, stress- related and somatoform
disorders; disorders of adult personality and behavior.
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